Skip to main content
Clinical Trials/NCT06131476
NCT06131476
Completed
Phase 1

Clinical Investigation of Visual Acuity in Contact Lens Wearers After Instillation of a Lipid- Based Lubricating Eye Drop

Johnson & Johnson Vision Care, Inc.2 sites in 1 country32 target enrollmentSeptember 16, 2020

Overview

Phase
Phase 1
Intervention
Blink® Tears eye drops
Conditions
Visual Acuity
Sponsor
Johnson & Johnson Vision Care, Inc.
Enrollment
32
Locations
2
Primary Endpoint
Visual Acuity (logMAR) at 10 Minutes Post Instillation
Status
Completed
Last Updated
last year

Overview

Brief Summary

This is a single visit, randomized, double masked, bilateral, non-dispensing, 2×2 crossover study to assess visual acuity.

Registry
clinicaltrials.gov
Start Date
September 16, 2020
End Date
October 10, 2020
Last Updated
last year
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Potential subjects must satisfy all of the following criteria to be enrolled in the study:
  • The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
  • Appear able and willing to adhere to the instructions set forth in this clinical protocol.
  • Between 18 and 69 (inclusive) years of age at the time of screening.
  • Subjects must be habitual spherical soft contact lens wearers.
  • Subjects must achieve visual acuity of 20/30 or better in each eye with their habitual contact lenses.

Exclusion Criteria

  • Potential subjects who meet any of the following criteria will be excluded from participating in the study:
  • The subject must not:
  • Currently pregnant or breast-feeding.
  • Any ocular or systemic allergies or disease which may interfere with the clinical trial (at the discretion of the investigator).
  • Any systemic disease, autoimmune disease, or use of medication which may interfere with the clinical trial (at the discretion of the investigator).
  • Any infectious diseases (e.g. hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g. HIV), by self-report.
  • History of any ocular or corneal surgery (e.g. RK, PRK, LASIK)
  • Participation in any pharmaceutical or medical device related clinical trial within 14 days prior to study enrollment.
  • History of binocular vision abnormality or strabismus.
  • Habitual wearers of rigid gas permeable lens within the past 3 months

Arms & Interventions

Control/Test

Eligible subjects who are habitual soft contact lens wearers will be randomized into the Test/Control sequence, to receive the CONTROL lubricating eye drops, with a washout period of 90 minutes between instillations. After the wash-out period, the TEST lubricating eye drops will be instilled.

Intervention: Blink® Tears eye drops

Test/Control

Eligible subjects who are habitual soft contact lens wearers will be randomized into the Test/Control sequence, to receive the TEST lubricating eye drops, with a washout period of 90 minutes between instillations. After the wash-out period, the CONTROL lubricating eye drops will be instilled.

Intervention: Blink® Tears eye drops

Test/Control

Eligible subjects who are habitual soft contact lens wearers will be randomized into the Test/Control sequence, to receive the TEST lubricating eye drops, with a washout period of 90 minutes between instillations. After the wash-out period, the CONTROL lubricating eye drops will be instilled.

Intervention: Investigational lipid eye drops

Control/Test

Eligible subjects who are habitual soft contact lens wearers will be randomized into the Test/Control sequence, to receive the CONTROL lubricating eye drops, with a washout period of 90 minutes between instillations. After the wash-out period, the TEST lubricating eye drops will be instilled.

Intervention: Investigational lipid eye drops

Outcomes

Primary Outcomes

Visual Acuity (logMAR) at 10 Minutes Post Instillation

Time Frame: 10 minutes post instillation

High contrast bright illumination monocular logMAR (Logarithm of the Minimum Angle of Resolution) visual acuity was assessed at distance (4 meters) using ETDRS Charts, near (40 cm) and intermediate (64 cm) using reduced Guillon-Poling charts. A value of 0.0 logMAR indicated a Snellen vision of 20/20. Lower logMAR visual acuity values indicate better vision. The average logMAR visual acuity for each treatment was reported.

Visual Acuity (logMAR) at 3 Minutes Post Instillation

Time Frame: 3 minutes post instillation

High contrast bright illumination monocular logMAR (Logarithm of the Minimum Angle of Resolution) visual acuity was assessed at distance (4 meters) using ETDRS Charts, near (40 cm) and intermediate (64 cm) using reduced Guillon-Poling charts. A value of 0.0 logMAR indicated a Snellen vision of 20/20. Lower logMAR visual acuity values indicate better vision. The average logMAR visual acuity for each treatment was reported.

Study Sites (2)

Loading locations...

Similar Trials